Validation of hepatitis B virus–related hepatocellular carcinoma prediction models in the era of antiviral therapy
Kyu Sik Jung, Seung Up Kim, Kijun Song, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Kwang‐Hyub Han – 6 August 2015 – Several risk prediction models have been created to predict hepatitis B virus (HBV)‐related hepatocellular carcinoma (HCC) occurrence, with promising results. However, their prognostic performances need to be validated in the era of antiviral therapy. From 2006 to 2011, patients with chronic HBV infection were recruited and those with a history of HCC or hepatic decompensation were excluded.